...
首页> 外文期刊>American Journal of Physiology >Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells
【24h】

Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells

机译:血清淀粉样蛋白A在猪冠状动脉和人冠状动脉内皮细胞中诱导内皮功能障碍

获取原文
获取原文并翻译 | 示例

摘要

Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 295: H2399-H2408, 2008. First published October 17, 2008; doi:10.1152/ajpheart.00238.2008.~he objective of this study was to determine the effects and mechanisms of serum amyloid A (SAA) on coronary endothelial function. Porcine coronary arteries and human coronary arterial endothelial cells (HCAECs) were treated with SAA (0, 1, 10, or 25 |i.g/ml). Vasomotor reactivity was studied using a myograph tension system. SAA significantly reduced endo-thelium-dependent vasorelaxation of porcine coronary arteries in response to bradykinin in a concentration-dependent manner. SAA significantly decreased endothelial nitric oxide (NO) synthase (eNOS) mRNA and protein levels as well as NO bioavailability, whereas it increased ROS in both artery rings and HCAECs. In addition, the activities of internal antioxidant enzymes catalase and SOD were decreased in SAA-treated HCAECs. Bio-plex immunoassay analysis showed the activation of JNK, ERK2, and iKB-a after SAA treatment. Consequently, the antioxidants seleno-L-methionine and Mn(III) tet-rakis-(4-benzoic acid)porphyrin and specific inhibitors for JNK and ERK1/2 effectively blocked the SAA-induced eNOS mRNA decrease and SAA-induced decrease in endothelium-dependent vasorelaxation in porcine coronary arteries. Thus, SAA at clinically relevant concentrations causes endothelial dysfunction in both porcine coronary arteries and HCAECs through molecular mechanisms involving eNOS downregulation, oxidative stress, and activation of JNK and ERK1/2 as well as NF-kB. These findings suggest that SAA may contribute to the progress of coronary artery disease
机译:血清淀粉样蛋白A诱导猪冠状动脉和人冠状动脉内皮细胞中内皮功能障碍。 AM j Physiol心脏Circ Physiol 295:H2399-H2408,2008. 2008年10月17日第一次出版; DOI:10.1152 / ajpheart.00238.2008。〜他本研究的目的是确定血清淀粉样蛋白A(SAA)对冠状动脉内皮功能的影响和机制。猪冠状动脉和人冠状动脉内皮细胞(HCAECs)用SAA(0,1,1,10或25 | I.g / ml)处理。使用据称张力系统研究了血管传动机反应性。 SAA响应于浓度依赖性方式,显着降低了猪冠状动脉的脊髓冠状动脉依赖性血管交,依赖于Bradykin。 SAA显着降低内皮一氧化氮(NO)合成酶(eNOS)mRNA和蛋白质水平,也没有生物利用度,而它在动脉环和HCAEC中增加了ROS。此外,在SAA处理的HCAEC中,内部抗氧化酶过氧化酶和SOD的活性降低。 Bio-Plex免疫测定分析显示SAA处理后JNK,ERK2和IKB-A的激活。因此,抗氧化剂Seleno-L-蛋氨酸和Mn(III)TET-RAKIS-(4-苯甲酸)卟啉和用于JNK和ERK1 / 2的特异性抑制剂有效地阻断了SAA诱导的eNOS mRNA降低和SAA诱导的内皮降低 - 猪冠状动脉中的依赖血管克化。因此,在临床相关浓度下的SAA导致猪冠状动脉和HCAEC中的内皮功能障碍,通过涉及eNOS下调,氧化应激和JNK和ERK1 / 2的活化以及NF-KB的分子机制以及NF-KB。这些研究结果表明Saa可能有助于冠状动脉疾病的进展

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号